Apr 9 |
Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround
|
Apr 9 |
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
|
Apr 6 |
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
|
Apr 1 |
Million-Dollar Bets: 3 Under-$15 Stocks With Massive Potential
|
Mar 26 |
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
|
Mar 26 |
Ocular Therapeutix files to sell 43.22M shares of common stock for holders
|
Mar 19 |
Ocular Therapeutics' Impressive Surge: A Strategic Insight
|
Mar 13 |
Decoding 6 Analyst Evaluations For Ocular Therapeutix
|
Mar 13 |
Q4 2023 Clearside Biomedical Inc Earnings Call
|
Mar 12 |
Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 34.74%: Read This Before Placing a Bet
|